Phase I trial to evaluate the safety and efficacy of tetracosactide patients with Duchenne muscular dystrophy

Trial Profile

Phase I trial to evaluate the safety and efficacy of tetracosactide patients with Duchenne muscular dystrophy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2016

At a glance

  • Drugs Tetracosactide (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Sep 2016 New trial record
    • 25 Aug 2016 According to Mallinckrodt media release, first patient of the trial was dosed in August 2016.
    • 25 Aug 2016 In August 2016, US FDA granted a fast-track designation to Mallinckrodt for its IND application for Synacthen Depot in the treatment of duchenne muscular dystrophy, according to Mallinckrodt media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top